Stragen
Marie Alvarez is a skilled pharmacovigilance professional with extensive experience in safety management and quality assurance within the pharmaceutical industry. Currently serving as a Pharmacovigilance Quality Assurance pharmacist at Servier since June 2024, Marie previously held the role of Pharmacovigilance Project Manager at STRAGEN SERVICES SAS, where responsibilities included managing safety services, conducting Root Cause Analysis, and overseeing regulatory monitoring. Prior experience includes serving as Pharmacovigilance Manager at Boehringer Ingelheim and as an extern in Clinical Trial Vigilance at Hospices Civils de Lyon, where Marie contributed to adverse event management and regulatory submissions. Academically, Marie holds a Doctorate in Pharmacy and a Master’s degree in Health Engineering from Université Claude Bernard Lyon 1, as well as several additional qualifications in biomedical research.
This person is not in any offices
Stragen
Focusing on innovation for health solutions since 1990, Stragen is a global player in the development, registration and distribution of Generic drugs and Consumer Health products. Starting as a small API trading platform 30 years ago in Geneva, Switzerland, today Stragen operates in over 60 markets through a network of dynamic and collaborative partners, employing over 150 people and working with 10 dedicated affiliates worldwide. As a result of decades of experience and expertise in R&D, combined with our continuous commitment to advancing public health, we invest in the fundamental research through to the delivery of innovative and trusted health solutions to address unmet medical needs. We focus on two core activities: • Selected and Advanced Generics • Consumer Health products Our specialized and passionate scientific team consistently operates under the latest quality standards to deliver Swiss tailor-made solutions with the final product 100% manufactured in Europe. At Stragen, we understand that business models need to be reinvented to work within our competitive and fast-changing environment of the Pharma industry. We have identified how we can positively diversify our activities beyond the historical development and licensing out of Generic+ products, to the development of Consumer Health products as well as the development through to proof of concept of patented new drugs.